← FDA DRUG APPROVALS

FDA ANDA · ANDA091558

MYCOPHENOLIC ACID

Sponsor: APOTEX INC

APPLICATION
ANDA091558
TYPE
ANDA
ORIGINAL APPROVAL
2012-08-21
LATEST ACTION
2026-07-29
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

MYCOPHENOLATE SODIUMPrescription
MYCOPHENOLATE SODIUM EQ 180MG BASE · TABLET, DELAYED RELEASE · ORAL
MYCOPHENOLATE SODIUMPrescription
MYCOPHENOLATE SODIUM EQ 360MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2026-07-29REMS · Supplement 29AP
2024-08-13REMS · Supplement 22AP
2023-11-28Labeling · Supplement 19 · standardAP
2023-11-28Labeling · Supplement 17 · standardAP
2023-11-28Labeling · Supplement 14 · standardAP
2021-08-11REMS · Supplement 18AP
2021-04-21REMS · Supplement 16AP
2021-01-15REMS · Supplement 12AP
2019-12-31Labeling · Supplement 8 · standardAP
2015-11-13REMS · Supplement 6AP
2014-08-19OriginalAP
2014-06-26Labeling · Supplement 3 · standardAP
2013-09-30REMS · Supplement 2AP
2012-09-25REMS · Supplement 1AP
2012-08-21OriginalOtherAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →